Ronnie Shapira-Frommer, MD, Discusses Multidisciplinary Care to Treat Gynecologic Malignancies

Video

CancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about her thoughts on the effect of the conference content across multidisciplinary specialties.

CancerNetwork® sat down with Ronnie Shapira-Frommer, MD, to discuss research that was presented at the Society of Gynecological Oncology (SGO) 2021 Virtual Annual Meeting on Women’s Cancer.

Shapira-Frommer discussed multidisciplinary care in the treatment of various gynecologic malignancies and how the data at the meeting facilitate this approach.

Transcription:

We have to face patients’ cancer as a multidisciplinary team with the strength of each expertise, including surgical, radiotherapy, and medical oncologist joined together. This is unique for this field of treatment. Pushing forward with the preclinical studies and with the data [from the SGO Annual Meeting], we can move forward patient care in the best of their interest, and for us as well.

Recent Videos
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Related Content